Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097193 - CHIMERIC ANTIGEN RECEPTORS FOR PHAGOCYTOSIS

Publication Number WO/2020/097193
Publication Date 14.05.2020
International Application No. PCT/US2019/060052
International Filing Date 06.11.2019
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 2039/5156
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5156expressing foreign proteins
A61K 2039/5158
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5158Antigen-pulsed cells, e.g. T-cells
A61K 39/0011
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0011Cancer antigens
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • VALE, Ronald D.
  • MORRISSEY, Meghan A.
  • WILLIAMSON, Adam P.
Agents
  • DANG, David V.
  • SHIEH-NEWTON, Terri
  • VANEVSKI, Filip
Priority Data
62/756,23506.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CHIMERIC ANTIGEN RECEPTORS FOR PHAGOCYTOSIS
(FR) RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES POUR LA PHAGOCYTOSE
Abstract
(EN)
The present disclosure generally relate to novel chimeric antigen receptors (CARs) that comprise an intracellular signaling domain of an engulfment receptor expressed on the surface of a phagocytic cell and activate the endogenous phagocytic signaling pathway. Also disclosed are compositions and methods useful for producing such CARs, nucleic acids encoding same, phagocytic cells that have been modified to include a targeted effector activity directed towards a cell of interest such as,e.g.,a cancer cell, as well as for modifying a cell and/or for the treatment of various health disorders such as cancer, including solid tumor and hematologic malignancy.
(FR)
La présente invention concerne d'une manière générale de nouveaux récepteurs antigéniques chimériques (CAR) qui comprennent un domaine de signalisation intracellulaire d'un récepteur de phagocytose exprimé à la surface d'une cellule phagocytaire et activent la voie de signalisation phagocytaire endogène. L'invention concerne également des compositions et des méthodes utiles pour produire de tels CAR, des acides nucléiques codant pour ceux-ci, des cellules phagocytaires qui ont été modifiées pour inclure une activité effectrice ciblée dirigée contre une cellule d'intérêt telle que, par exemple, une cellule cancéreuse, ainsi que pour modifier une cellule et/ou pour le traitement de divers troubles de la santé tels que le cancer, y compris des tumeurs solides et des malignités hématologiques.
Latest bibliographic data on file with the International Bureau